Here are the coronavirus stories around the globe you need to know about today:


Antibody levels in cases with mild COVID-19, the level of disease most people have, appear to drop by half within 5 weeks, new reports say. The results, published on the internet in a letter sent to the editor of The New England Journal of Medicine. “put substantial numbers on the decline of antibodies after early infection,” study author University of California, Los Angeles professor of medicine Otto Yang, MD reported. The speed in the decline of antibodies at 36 days “is startling compared to other infections,” he also said. Albeit interpreting the data comes with a few caveats, the study indicates that there is “zero cause for anybody to be getting an antibody test medically right now.” Yang also reportedly said.


A century-old approach to preventing the widespread of infectious diseases involves the use of ultraviolet light or germicidal UV. If delivered in the right dose, it can wipe out viruses, bacteria, and other microorganisms. “Although it’s not perfect, it probably gives the most effective solution for aerosol disinfection” in the current pandemic, David Sliney, a Johns Hopkins University faculty member and longtime researcher said.


The coronavirus might be spreading quicker in the United States than labs can test for it. This prompts a more slow turnaround time for results, and it affects contact tracing. States disappointed by private research centers in long turnarounds for COVID-19 test outcomes are scrambling to discover approaches to rescue their testing programs, Kaiser Health News reports.

2 to 3 days is essential to successfully track and follow contacts and advise individuals that they may have been presented to the coronavirus.

The National Institutes of Health (NIH) expect to encourage COVID-19 testing that will cover 2% of the US populace, around 6 million individuals every day, by December. That testing rate would be eight to multiple times higher than the current every day rate, NIH Director Francis Collins, MD and associates write in an article distributed online in the New England Journal of Medicine.


Sometime around late March to mid-May, it’s probable that 10 times more COVID19 infections happened than the number of cases that were reported during that time, as per a new research by the CDC’s COVID19 Response Team.

Published Tuseday in the journal JAMA Internal Medicine, the study looked for antibodies in 10 locations across the US. In San Francisco, 1% of samples had antibodies in late April, as compared with nearly 7% in New York City, which was collected in late March.

“It is likely that greater than 10 times more SARS-CoV-2 infections occured than the number of reported COVID19 cases; most persons in each site, however, likely had no detectable SARS-CoV-2 antibodies,” the authors wrote.

A research team analyzed blood samples of more than 16,000 people in 10 states: San Francisco, Connecticut, Florida, Louisiana, Minnesota, Missouri, New York, Philadelphia, Utah, and Washington.

The team also assessed that the number of positive cases ranged somewhere between 6 to 24 times the number of reported cases. In Connecticut, for instance, they estimated that 176,000 infections occured from March through May, which was about 6 times greater than the 29,000 cases reported in early May. In Missouri, the team estimated that 162,000 infections occured which was almost 24 times greater than the 7,000 that was reported.

Most samples had no antibodies, which ranged from 1% to 7% across the locations. They didn’t find any association between the presence of antibodies based on age or gender.


Acute kidney injury is found in a considerable minority of patients with extreme COVID-19, no proof of the nearness of SARS-CoV-2 was found in kidney biopsies from a little arrangement of such patients, as per specialists.

“Kidney injury happens in more than 33% of hospitalized COVID-19 patients, and different impetuses have been proposed,” Purva Sharma, MD, revealed to Reuters Health News. “Our kidney biopsy research shows that the kidney injury from COVID-19 infection occurs because of entanglements of the ailment and isn’t a result of direct popular contamination of the kidney.”


Specialists are making “acceptable advancement” in creating immunizations against COVID-19, with a bunch in stage 3 preliminaries, yet their first use can’t be regular until mid-2021, a World Health Organization master said. WHO is attempting to guarantee reasonable antibody dispersion, yet meanwhile, it is critical to smother the infection’s spread, said Mike Ryan, top of WHO’s crises program.”Sensibly, it will be the initial segment of one year from now before we begin seeing individuals getting inoculated,” he said during an open occasion via web-based networking media.